Mahesh Umapathysivam

Great to see our research picked up by @theprojecttv. Proud that our work is helping to progress #precisionmedicine in diabetes care. Thank you to @DiabetesAus, @wellcometrust and @The_MRC for the support. link.springer.com/article/10.118…

Out this week in @GenomeMedicine - our work following up on how genetic variation in the PAM gene alters risk for #T2D & response to treatment. Carriers of PAM T2D-risk alleles are #GLP1resistant Download the paper for free here 👉 rdcu.be/fdFxB @StanfordPedEndo @StanfordMed

Excited to update that our latest work on the role of #type2diabetes PAM gene is finally out in hashtag#GenomeMedicine. We build on our 2018 study which demonstrated that T2D-risk alleles at the PAM locus result in a loss of function leading to reduced insulin content and altered dynamics of insulin secretion. We now show that they also lead to "GLP-1 resistance" in multiple human studies and in a murine model. We don't have all the answers but with a "lot of help from our friends" we have ruled out many potential explanations for the GLP-1 resistance and propose several new avenues for exploration. I am so proud of this collaborative work with Markus Stoffel which has been championed by two incredible early career academics - @MUmapathysivam and @ElisaAraldi both who are now independent investigators running their own research programs. This work started during my time in @OCDEM at the @RDMOxford and involved fantastic colleagues with complementary expertise from across North America and Europe. THE PAMTASTIC TEAM include...... @BruceVerchere @markmccarthyoxf @ezpearson @angusgjones @BHastoy Jens Holst, Andrew Hattersley, Fredrik Karpe, Mette M Rosenkilde, Torben Hansen, Adem Yesuf Dawed, Rury R Holman, Shahana Sengupta, Soren Krogsgaard Thomsen........ 🙏 Thank you to our funders including @wellcometrust , @NIDDKgov and @The_MRC @StanfordMed @StanfordPeds @StanfordEndo @StanfordPedEndo @StanfordDRC link.springer.com/article/10.118…

The ESA Poster Awards are awarded to the highest scoring poster presentations including a Q&A with the judging committee at the poster sessions. Congratulations to the awardees for 2024: @asmeakin - Basic Science @MUmapathysivam - Clinical Tomasz Block - Clinical Case Report

ICYMI: #ENDO2024 #Diabetes News Conference | Drs. Mojca Jensterle Sever; @JenniferTichMD; @MUmapathysivam; and @carlosfermin_99 cover #socialvulnerability + #bloodsugarcontrol, #testosterone + #waistsize, #prediabetes, and #semaglutide + taste perception: bit.ly/3RgvySN

#ENDO2024 #diabetes news conference: @MUmapathysivam's research found testosterone appears to protect against type 2 #diabetes risk in men under 65. bit.ly/4bGe6iO

So proud of our honours student, Caitlin Burt, winner of the NMT student award at the #ANZSNM24 ASM - @UniversitySA , @UniofAdelaide , @CRENutrition, @anzsnm1969, with co-supervisors @CristinaBlefari @MUmapathysivam

SGLT2i DKA was associated with milder presentation, twice the median time to resolution and half the amount of insulin administered on standard T1D-DKA dynamic insulin infusion protocol when compared to individuals with T1D-DKA of a similar age. ja.ma/4944AUm

We describe 2 cases of severe ketoacidosis in individuals without #diabetes being treated with SGLT2i for heart failure @DiabetesCareADA diabetesjournals.org/care/article/d…

Rare but real-Euglycemic ketoacidosis in two HFrEF subjects without #diabetes with use of SGLT-2 inhibitors @DiabetesCareADA diabetesjournals.org/care/article/d…

Today we updated our lab 🥼 this is us wall with new papers & team photos! @StanfordPedEndo @yunkyeong_lee @tamadher_aa

New from @annagloyn Human carriers of hypomorphic #T2D risk alleles in the gene encoding peptidyl-glycine alpha-amidating monooxygenase (PAM) exhibit reduced glucose-lowering responses to Rxment with GLP-1R agonist, likely not related to #islet actions medrxiv.org/content/10.110…

Thank you to all the researchers across 3 continents who have contributed to this work, the research participants and the funding bodies who have supported this work. Thank you and ttfn! @RDMOxford @rhodes_trust @The_MRC @wellcometrust @stanfordPedEndo /10

In a meta-analysis of 3 pharmacogenetics studies we show reduced efficacy GLP-1RA in carriers of PAM LoF alleles as measured by HbA1c 6 months after starting therapy #personalisedmedicine./9

I'm excited & proud to share work from my DPhil @oxforduni & an amazing collaboration with @annagloyn, @markmccarthyoxf, @ElisaAraldi & Markus Stoffel. We show that variants in the #T2D risk gene PAM alter GLP-1 levels & response to GLP-1 receptor agonists medrxiv.org/content/10.110…